| Literature DB >> 35328756 |
Agnieszka Krzemińska1, Natalia Kwiatos1, Franciela Arenhart Soares1, Alexander Steinbüchel1.
Abstract
The three-dimensional structure of tyrosinase has been crystallized from many species but not from Homo sapiens. Tyrosinase is a key enzyme in melanin biosynthesis, being an important target for melanoma and skin-whitening cosmetics. Several studies employed the structure of tyrosinase from Agaricus bisporus as a model enzyme. Recently, 98% of human genome proteins were elucidated by AlphaFold. Herein, the AlphaFold structure of human tyrosinase and the previous model were compared. Moreover, tyrosinase-related proteins 1 and 2 were included, along with inhibition studies employing kojic and cinnamic acids. Peptides are widely studied for their inhibitory activity of skin-related enzymes. Cyanophycin is an amino acid polymer produced by cyanobacteria and is built of aspartic acid and arginine; arginine can be also replaced by other amino acids. A new set of cyanophycin-derived dipeptides was evaluated as potential inhibitors. Aspartate-glutamate showed the strongest interaction and was chosen as a leading compound for future studies.Entities:
Keywords: AlphaFold; molecular docking; tyrosinase; tyrosinase-related protein 1; tyrosinase-related protein 2
Mesh:
Substances:
Year: 2022 PMID: 35328756 PMCID: PMC8950311 DOI: 10.3390/ijms23063335
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Proposed melanin biosynthesis involving the three tyrosinase-related proteins.
Figure 2Pairwise sequence alignment of TYR and abTYR sequences used in this study. Magenta, CuA binding pattern; blue, CuB binding pattern; orange, EFG pattern.
Figure 3Three-dimensional structures of tyrosinases: (A) TYR, (B) TYRP1, (C) TYRP2. Grey, tyrosinase domain; magenta, CuA binding pattern; blue, CuB binding pattern; orange, EFG pattern; brown, copper atoms; green, zinc atoms.
The binding affinity values obtained for selected ligands in complex with tyrosinase enzymes reported in kcal∙mol−1.
| Ligand | abTYR | TYR | TYRP1 | TYRP2 |
|---|---|---|---|---|
| −5.9 | −6.0 | −5.9 | −6.0 | |
| −6.4 | −6.7 | −6.3 | −6.8 | |
| −5.4 | −5.5 | −6.1 | −5.7 | |
| −6.3 | −6.3 | −6.4 | −6.6 | |
| −5.4 | −5.3 | −5.2 | −6.0 | |
| −5.2 | −5.3 | −4.9 | −5.6 | |
| −5.7 | −5.8 | −5.7 | −6.1 | |
| −5.4 | −5.6 | −5.2 | −5.4 | |
| −7.1 | −7.3 | −7.0 | −7.0 | |
| −8.0 | −8.0 | −7.5 | −7.8 |
Figure 4Maps of electrostatic potential for (A) Lig2, (B) Lig4, and (C) the active site of TYR.